HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


B&BW ’08 goals

This article was originally published in The Rose Sheet

Executive Summary

Bath & Body Works will focus on a few "key" priorities this year, including reinvigorating the brand, creating more brand consistency, and stemming current negative sales trend due to traffic decline in retail locations, B&BW CEO Diane Neal says during Limited Brands year-end (ended Feb. 2) earnings presentation Feb. 28. Company is focused on growing key brands C.O. Bigelow, True Blue Spa, aromatherapy and fragrant body care, she says. Limited Brands net sales for the year fell 5% to $10.13 bil. due to "transformational changes" that occurred through the year, while net income grew 6.2% to $718 mil. Limited Brands says disappointing results in 2007 "better position" the firm to prepare for core brand growth in 2008. In light of the retail environment, the number of projects planned for 2008 are reduced by 25%, with the goal of reducing planned capital expenditures of about $85 mil...

You may also be interested in...

Formycon Chief Sees COVID-19 Boosting Biosimilars

Formycon’s CEO has offered the latest indication that the coronavirus outbreak could provide a tailwind for biosimilars, as the firm gave an update on its biosimilars pipeline – including ranibizumab, ustekinumab, aflibercept and an undisclosed molecule, as well as other unrevealed projects – and how it has been affected by the pandemic.

PDUFA Renewal Negotiations: What Does Industry Want Now?

With the formal, virtual kick-off meeting set for 23 July, US FDA and sponsors are looking at a transformed landscape as they discuss what the next five years of user fees will look like.

Keeping Track: Approvals For Phexxi, Kynombi; New Claims For Lynparza, Alunbrig, Tecentriq; Intercept May Miss NASH User Fee Date

The latest drug development news and highlights from the Pink Sheet US FDA Performance Tracker.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts